GRAIL, Inc. (GRAL)
GRALNASDAQ-GSMedical Specialities
$124.74
-3.34 (-2.61%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $5.61bn
- P/E
- –
- EPS, last 4 quarters
- $-9.50
- Dividend yield
- –
- Day range
- –
- 52-week range
- $41.50 to $166.48
- Average volume
- 1.13m
- Previous close
- $128.08
Analysts
10 coveringHold5 buy, 5 hold, 0 sell
Targets a year out average $137.50, +10.2% from here
Earnings
next estimate $-2.30Next report
Dec 2025
+26.7%
Mar 2026
+23.7%
Jun 2026
+12.0%
Sep 2026
+20.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $43.60m | $40.78m | $44.69m | $37.53m |
| Gross profit | -$11.14m | -$14.31m | -$12.57m | -$18.11m |
| Operating income | -$124.41m | -$135.76m | -$173.78m | -$144.62m |
| Net income | -$99.18m | -$93.19m | -$110.25m | -$103.57m |
Last four quarters: revenue $166.60m, margin -243.8%, free cash flow -$312.00m
News
6 latest- Insider Sale: Chief Financial Officer of $GRAL Sells 8,000 SharesQuiver Quantitative · Jul 17, 2025
- GRAIL Earnings Results: $GRAL Reports Quarterly EarningsQuiver Quantitative · May 13, 2025
- Lobbying Update: $500,000 of GRAIL INC. (FORMERLY GRAIL LLC) lobbying was just disclosedQuiver Quantitative · May 5, 2025
- New Analyst Forecast: $GRAL Given $32.0 Price TargetQuiver Quantitative · Apr 23, 2025
- Lobbying Update: $30,000 of GRAIL INC. lobbying was just disclosedQuiver Quantitative · Jan 21, 2025
- Lobbying Update: $50,000 of GRAIL INC. lobbying was just disclosedQuiver Quantitative · Jan 17, 2025
The company
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- grail.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.